Maria Teresa Villa de Brito

Maria Teresa Villa de Brito

Auto-generated profile, based on publicly available information

Maria Teresa Villa de Brito

Centro de Investigação Interdisciplinar em Sanidade Animal (CIISA), Faculdade de Medicina Veterinária, Technical University of Lisbon (TULisbon), Av. Universidade Técnica, 1300-477 Lisbon, Portugal

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2010 in Veterinary Immunology and Immunopathology
Verified
Journal Article
Closed access
GAGraca Alexandre-Pires
Graca Alexandre-Pires
MBMaria Teresa Villa de Brito
Maria Teresa Villa de Brito
CACármen Algueró
Cármen Algueró
CMCatarina Gregório Martins
Catarina Gregório Martins
OROlivia Roos Rodrigues
Olivia Roos Rodrigues
Gabriela Santos-GomesGabriela Santos-Gomes
Gabriela Santos-Gomes

23 October 2013 in Irish Veterinary Journal
Verified
Journal Article
Open access
PDF file
RLRodolfo Oliveira Leal
Rodolfo Oliveira Leal
Solange GilSolange Gil
Solange Gil
MBMaria Tv Brito
Maria Tv Brito
DMDavid McGahie
David McGahie
MNMaria Mre Niza
Maria Mre Niza
LTLuís Tavares
Luís Tavares
Feline Chronic Gingivostomatitis Syndrome (FCGS) is a common disease in clinical practice. Among the therapeutic options available, long-acting corticosteroids are frequently used due to their anti-inflammatory and immunosuppressive properties. Although they may improve the clinical symptoms, they can lead to a progressive form of the disease that becomes refractory to treatment. Furthermore, their direct relationship with type II diabetes mellitus (DM) is well known. Consequently, these drugs are controversial and not recommended for routine management of FCGS. Recombinant feline interferon-omega (rFeIFN-ω) is an immunomodulatory compound. Recently, its daily oral administration has been shown to be successful in treating refractory cases of FCGS. This case study describes two clinical cases of type II DM complicated by FCGS. Both animals were calicivirus positive and they had been previously treated with long-acting corticosteroids, which may have been the major cause of DM. The two cats were treated with glargine insulin (Lantus, starting dose 1 IU/cat twice daily (BID)), achieving remission 10 and 18 weeks later respectively. Considering the difficulty with control of FCGS in these animals, an oral daily dose of rFeIFN-ω was started as an alternative to long-acting corticosteroids. In both cats oral clinical signs gradually improved and 60 days after the start of therapy the owners reported a significant relief of pain during mastication. According to the authors’ knowledge, this is the first case report that describes the successful use of rFeIFN-ω in the management of FCGS in type II diabetic cats, in which long-acting corticosteroids are contraindicated.

1 March 2002 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
MBM T Villa De Brito
M T Villa De Brito
ACAntónio Manuel Teixeira Martins do Canto
António Manuel Teixeira Martins do Canto
JCJ H Duarte Correia
J H Duarte Correia
Rodrigo CunhaRodrigo Cunha
Rodrigo Cunha
MMM C Marques
M C Marques